🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Liège
Clinical trial register · Belgium

Clinical Trials in Liège, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Belgium and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3062 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
3062
Studies in scope
all four open statuses
1741
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Leuven 1265 Brussels 1116 Ghent 1043 Liège 564 Edegem 437
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca37 AbbVie30 University of Liege29 Janssen Research & Development, LLC26 Centre Hospitalier Universitaire de Liege19
Site location
Leuven1265 Brussels1116 Ghent1043 Liège564 Edegem437
All 201 locations
Target enrolment
to

Trials with a site in Liège

565 of 3062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Belgium
Start
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Leuven, Liège
2027-02-03
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Yvoir, Leuven, Brussels, Kortrijk, Liège
2026-12-16
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Ghent, Jette, Leuven, Liège
2026-11-09
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
Anderlecht, Bonheiden, Ghent, Leuven, Liège, Ostend, Woluwe-Saint-Lambert
2026-09-30
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
DrugHizentra
CSL Behring
Phase 3
63
Edegem, Roeselare, Ghent, Liège
2026-09-15
Recruiting
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
466
Leuven, Liège, Roeselare
2026-09-14
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
DrugINCA033989
Incyte Corporation
Phase 3
426
Anderlecht, Brussels, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2026-09-08
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 3
70
Leuven, Liège
2026-09-01
Not yet open
New Consciousness Indicators (NCI)
NCT07786298Consciousness Assessment
University of Liege
Observational
100
Liège
2026-09
Not yet open
PRotEin Provision in Critical IllneSs -2
NCT07529522Critical Illness, Intensive Care (ICU)
Ziekenhuis Oost-Limburg
Not applicable
1,026
Antwerp, Genk, Ghent, Hasselt, Jette, Kortrijk, Leuven, Liège
2026-09
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714Systemic Lupus Erythematosus
AstraZeneca
Phase 2
24
Brussels, Ghent, Leuven, Liège
2026-08-31
Recruiting
A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot Ulcers
NCT07783087Diabetic Foot Ulcer (DFU)
Flen Health
Not applicable
64
Bonheiden, Mechelen, Ghent, Charleroi, Liège, Arlon, Leuven, Bruges
2026-08-10
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Brussels, Edegem, Gilly, Leuven, Liège, Namur
2026-08-05
By invitation
Neuromuscular Function and Performance in Athletes With or Without Bruxism
NCT07556211Bruxism
Mainjot Amélie
Observational
120
Liège
2026-08-01
Not yet open
Natural History Study for Patients With Nemaline Myopathy in Belgium
NCT07201636Nemaline Myopathy
Centre Hospitalier Universitaire de Liege
Not applicable
10
Liège
2026-08
Not yet open
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
NCT07682129Duchenne Muscular Dystrophy (DMD)
DrugsENTR-601-44·ENTR-601-45
Entrada Therapeutics, Inc.
Phase 2
80
Ghent, Leuven, Liège
2026-08
Not yet open
Digital Monitoring of Upper Limb Function in Non-Ambulant DMD
NCT07664124Duchenne Muscular Dystrophy (DMD)
Centre Hospitalier Universitaire de Liege
Not applicable
50
Liège
2026-07-30
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Brussels, Ghent, Jette, Leuven, Liège, Yvoir
2026-07-27
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Brussels, Edegem, Leuven, Liège
2026-07-10
Not yet open
Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon
NCT07650578Coronary Arterial Disease (CAD), Calcific Coronary Arteriosclerosis
University of Mons
Not applicable
200
Mons, Bonheiden, Brussels, Libramont, Liège, Lodelinsart
2026-07
Recruiting
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
NCT07727694Pediatric Cancer
Universitaire Ziekenhuizen KU Leuven
Observational
1,600
Antwerp, Brussels, Ghent, Leuven, Liège
2026-07
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Edegem, Brussels, Ghent, Leuven, Liège
2026-06-01
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Genk, Ghent, Kortrijk, Liège
2026-05-17
Not yet open
Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
NCT07455318Rabies (Healthy Volunteers)
Institute of Tropical Medicine, Belgium
Phase 3
561
Antwerp, Brussels, Ghent, Jette, Liège, Neder-Over-Heembeek
2026-05-15
Recruiting
First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss
NCT07637981Age-related Hearing Loss
Dendrogenix
Phase 2
24
Liège
2026-05-13
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Bruges, Brussels, Genk, Ghent, Leuven, Liège
2026-05-12
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
Liège, Roeselare
2026-05-11
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Antwerp, Bruges, Brussels, Edegem, Ghent, Leuven, Liège, Roeselare
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Antwerp, Bruges, Brussels, Edegem, Ghent, Leuven, Liège, Roeselare
2026-04-29
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
Brussels, Ghent, Liège
2026-04-23
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
University Medical Center Groningen
Observational
10,000
Ghent, Leuven, Liège
2026-04-21
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Brussels, Genk, Ghent, Leuven, Liège, Roeselare
2026-04-21
Active, closed
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
NCT07503210Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
606
Diepenbeek, Kortrijk, Liège, Ostend
2026-04-21
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Diepenbeek, Ghent, Liège
2026-04-14
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Anderlecht, Brussels, Edegem, Ghent, Gilly, Leuven, Liège, Yvoir
2026-04-09
Recruiting
Orthodontic and Articular Effects of the One-Step No-Prep Protocol
NCT07533240Tooth Wear, Orthodontic Extrusion
Mainjot Amélie
Not applicable
30
Liège
2026-04
Not yet open
Effects of a Targeted Prevention Program on Change-of-Direction Biomechanics and Performance in Elite Female Soccer Players
NCT07523178Anterior Cruciate Ligament Injury
University of Liege
Not applicable
51
Liège
2026-03-30
Recruiting
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
NCT07736937Ovarian Cancer
DrugsCarbo·TUB-040
Tubulis GmbH
Phase 1/2
72
Brussels, Ghent, Leuven, Liège
2026-03-30
Active, closed
Eccentric Cycling in Multiple Sclerosis Rehabilitation
NCT07316764Multiple Sclerosis, Rehabilitation, Neuro-Degenerative Disease, Neurorehabilitation
University of Liege
Not applicable
60
Liège
2026-03-27
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Leuven, Liège
2026-03-17
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
Bruges, Hasselt, Leuven, Liège
2026-03-16
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Aalst, Brussels, Leuven, Liège, Roeselare
2026-03-16
Recruiting
Ankle vs. Hip vs. Combined Strengthening in Chronic Ankle Instability
NCT07606534Chronic Ankle Instability, CAI, Ankle Sprain
University of Liege
Not applicable
45
Liège
2026-03-02
Recruiting
Virtual Reality as a Tool for Training Public Speaking Skills in Higher Education Students
NCT07392554Voice, Speech, Virtual Reality Simulation, Healthy Adult
University of Liege
Not applicable
80
Liège
2026-03
Recruiting
Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms
NCT07529275Complex Abdominal Aortic Aneurysms
iVascular S.L.U.
Not applicable
165
Bonheiden, Genk, Ghent, Gilly, Hasselt, Liège
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Aalst, Leuven, Liège
2026-02-16
Recruiting
Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
NCT07388966Achondroplasia, Hypochondroplasia
SYSNAV
Observational
140
Liège
2026-02-06
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Brussels, Edegem, Ghent, Leuven, Liège, Namur, Yvoir
2026-02-05
Recruiting
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
NCT06831955Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven
Phase 2
356
Antwerp, Brussels, Ghent, Hasselt, Kortrijk, Leuven, Liège, Namur
2026-02-01
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Ghent, Edegem, Jette, Liège, Yvoir
2026-01-22
Recruiting
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT07308132Lymphoma, Non-Hodgkin
DrugsJNJ-87801493·Loncastuximab Tesirine·Polatuzumab Vedotin·Vincristine
Janssen Research & Development, LLC
Phase 1
340
Edegem, Liège
2026-01-20
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsSacituzumab tirumotecan·Paclitaxel·Bevacizumab·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,023
Edegem, Brussels, Charleroi, Liège, Ghent, Leuven
2026-01-19
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Edegem, Leuven, Liège
2026-01-16
Active, closed
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Chronic Hepatitis D Infection
DrugBrelovitug
Mirum Pharmaceuticals, Inc.
Phase 3
80
Brussels, Edegem, Liège
2026-01-14
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Edegem, Yvoir, Roeselare, Brussels, Liège
2026-01-02
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Brussels, Ghent, Liège
2025-12-29
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Aalst, Antwerp, Ghent, La Louvière, Liège
2025-12-19
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Anderlecht, Charleroi, Hasselt, Leuven, Liège
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Brussels, Ghent, Leuven, Liège
2025-12-09
Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
Liège, Ghent
2025-12-08
Recruiting
Lifestyle Intervention to Improve Twin Pregnancy Outcomes
NCT07270640Twin Pregnancy, Dichorionic
Universitaire Ziekenhuizen KU Leuven
Not applicable
81
Brussels, Genk, Leuven, Liège
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Anderlecht, Edegem, Leuven, Liège, Roeselare
2025-12-04
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Brussels, Edegem, Hasselt, Kortrijk, La Louvière, Liège, Sint-Niklaas
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Brussels, Ghent, Liège
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Edegem, Leuven, Liège, Merksem (Antwerpen)
2025-12-02
Recruiting
Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening
NCT07286565Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD)
Centre Hospitalier Universitaire de Liege
Not applicable
100
Liège
2025-12-01
Recruiting
Assessment of Neurofilaments Levels in Premature Newborns: Study of Their Early Development
NCT07159555Healthy Participants
Centre Hospitalier Universitaire de Liege
Observational
15
Liège
2025-12-01
Recruiting
Metabolic and Muscle Profile in ICU Survivors
NCT07329530Critical Illness, Major Abdominal Surgeries
Anne-Françoise Rousseau
Not applicable
100
Liège
2025-12-01
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Charleroi, Liège, Hasselt, Ghent
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
Jette, Leuven, Liège
2025-11-25
Not yet open
Impact of a Physical Activity Intervention on Cardiometabolic Health, Mental Health, and Lifestyle Factors.
NCT07237893Healthy
University of Liege
Not applicable
1,000
Hasselt, Liège
2025-11-24
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Leuven, Brussels, Edegem, Ghent, Liège
2025-11-19
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
400
Brussels, Ghent, Leuven, Liège, Namur
2025-11-13
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Brussels, Kortrijk, Leuven, Liège
2025-11-12
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
Ghent, Leuven, Liège, Sint-Niklaas
2025-11-06
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brussels, Woluwe-Saint-Lambert, Kortrijk, Liège, Charleroi
2025-11-03
Recruiting
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
NCT07100730Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
50
Leuven, Liège
2025-11-02
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Brussels, Liège
2025-10-27
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Edegem, Gilly, La Louvière, Liège, Mons
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Aalst, Brussels, Hasselt, Leuven, Liège, Mons, Roeselare
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Bonheiden, Edegem, Anderlecht, Brussels, Ghent, Leuven, Liège
2025-10-23
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
675
Genk, Sint-Niklaas, Liège
2025-10-08
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Brussels, Ghent, Leuven, Liège, Ostend, Tournai
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Brussels, Ghent, Leuven, Liège, Ostend, Tournai
2025-10-01
Recruiting
Iliopsoas (IPB) and Pericapsular Nerve Group (PENG) Blocks Comparison on Analgesia and Recovery After Total Hip Arthroplasty
NCT06964282Total Hip Arthroplasty (THA), Postoperative Pain Management, Peripheral Nerve Blocks, PENG Block
University of Liege
Not applicable
118
Liège
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Genk, Liège, Sint-Niklaas, Yvoir
2025-10-01
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Wilrijk, Ghent, Liège
2025-09-30
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
Brussels, Liège, Namur
2025-09-29
Recruiting
Observational BELgian Registry of Implanted EV-ICD to Evaluate Parameters and Complications of the New Device in Real World Settings
NCT07156851Implantable Cardioverter Defibrillator (ICD)
AZ Sint-Jan AV
Observational
100
Antwerp, Bruges, Brussels, Ghent, Liège
2025-09-25
Recruiting
Gait Analysis Parameter and Upper Limb Evaluation in Control Participants
NCT07136506Healthy Participants
Centre Hospitalier Universitaire de Liege
Not applicable
200
Liège
2025-09-24
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Genk, Liège, Aalst, Bruges, Ghent
2025-09-22
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Ghent, Leuven, Liège
2025-09-15
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Anderlecht, Ghent, Kortrijk, Liège, Mechelen, Yvoir
2025-09-04
Recruiting
The Impact of a 3D Imaging Tool on Reducing Gum Recession During Orthodontic Treatment With Aligners
NCT07513792Orthodontic, Gingival Recession, Cone-Beam Computed Tomography
University of Liege
Not applicable
40
Liège
2025-09-04
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Bruges, Brussels, Ghent, Kortrijk, La Louvière, Liège, Ottignies, Wilrijk
2025-09-02
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
140
Brussels, Leuven, Liège
2025-09-02
Recruiting
Selective Versus Contiguous Connective Tissue Grafts in the Modified Tunnel Technique
NCT07453147Gum Recession
Centre Hospitalier Universitaire de Liege
Not applicable
32
Liège
2025-09-01
Not yet open
Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
NCT07152067Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume, CAPRA SCORE ≤5
Centre Hospitalier Universitaire de Liege
Phase 2
146
Arlon, Liège
2025-09
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
NCT07038824Duchenne Muscular Dystrophy (DMD)
DrugENTR-601-45
Entrada Therapeutics, Inc.
Phase 1/2
24
Ghent, Leuven, Liège
2025-08-30
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Antwerp, Brussels, Ghent, Jette, Leuven, Libramont, Liège, Namur
2025-08-26
Rows per page Showing 1–100 of 565
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Belgian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-belgium/city/li-ge

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Belgium and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,062 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 565 of those studies with a site in Liège.

How many clinical trials are recruiting in Liège?

289 of the 565 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 16 have not yet opened recruitment, 247 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Liège), 565 studies
PhaseStudiesRecruitingShare
Phase 326511246.9%
Phase 2773513.6%
Observational744413.1%
Not applicable724812.7%
Phase 1/225174.4%
Phase 2/323174.1%
Phase 11893.2%
Phase 41171.9%

Most active sponsors

Lead sponsors with the most studies (Liège)
Lead sponsorStudiesRecruiting
AstraZeneca3712
AbbVie3016
University of Liege2919
Janssen Research & Development, LLC2611
Centre Hospitalier Universitaire de Liege1913
Hoffmann-La Roche185
Bristol-Myers Squibb157
Boehringer Ingelheim1411
Incyte Corporation125
Novartis Pharmaceuticals121
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.